MAP2K7 and cancer: These data provide a probable explanation for the response heterogeneity of MEK/ERK inhibition in cancer treatment because the regulatory effect of MEK/ERK inhibition on PDE4D activity largely depends on the cell-type/environment and finally leads to the different changes of cAMP level.